GeneDx Holdings And 2 AI Healthcare Stocks To Watch

BlackRock chief Larry Fink recently warned that halting AI data center buildouts in the US could risk tipping the economy into recession. That kind of comment shows how deeply AI infrastructure is now woven into growth stories, including healthcare. As capital chases AI infrastructure, investors are looking at AI in medicine too. This article highlights three AI driven healthcare stocks from our screener that aim to benefit from this shift.

The three stocks below are just a starting sample from this theme. The full screen surfaced 31 more AI healthcare companies with equally detailed narratives that are not covered here. If you want to identify and analyze your own highest conviction plays in this space, head straight to the Transformative Artificial intelligence (AI) Healthcare Stocks screener.

GeneDx Holdings (WGS)

Overview: GeneDx Holdings is a genomics company that uses AI driven sequencing analysis to deliver whole exome and genome testing for rare diseases, hereditary risk, and cancer.

Operations: GeneDx reports about US$423 million from segment adjustments and US$31 million from Fabric Genomics and Legacy Sema4, all generated in the United States.

Market Cap: US$1.9 billion

For the Transformative AI Healthcare theme, GeneDx Holdings matters because its AI heavy genomic engine aims to turn raw DNA data into faster, clearer answers for complex conditions.

"Rapid long-term reimbursement gains from Medicaid and commercial payers are unlikely to be sustainable as government cost-containment efforts intensify in response to rising healthcare spending, increasing the risk that reimbursement rates for advanced diagnostics will decline and directly pressure GeneDx's future revenue growth and gross margins."

What happens to GeneDx’s AI powered testing story will hinge on how one quiet shift in economic incentives filters through to genomic demand.

Those shifting incentives are exactly why the full narrative for GeneDx Holdings digs into how GeneDx could still accelerate if reimbursement pressure and genomic demand start to decouple.

CeriBell (CBLL)

Overview: CeriBell delivers AI enabled, point of care EEG systems that help acute care teams detect seizures and monitor brain activity in real time.

Operations: CeriBell generates US$102 million from diagnostic kits and equipment, all from customers in the United States.

Market Cap: US$1.0 billion

CeriBell matters for this AI healthcare theme because its Ceribell System with Clarity aims to turn neurologic emergencies into faster, data driven decisions at the bedside and through remote monitoring.

"Ongoing shift within hospitals to formal, guideline based seizure management protocols for stroke, cardiac arrest and hemorrhagic patients is driving broader, mandated EEG use, supporting higher utilization per account and an increasing mix of high margin recurring revenue."

What happens if one quiet pressure on CeriBell’s AI EEG adoption changes the balance between rapid adoption and future margins.

If you want to see how that pressure could actually accelerate CeriBell’s EEG adoption curve, read the full narrative for CeriBell for the full risk reward picture.

HealthStream (HSTM)

Overview: HealthStream provides SaaS tools that use AI powered competency and workforce platforms to help healthcare providers train, credential, and manage clinicians.

Operations: HealthStream generates about US$321 million from Internet Software & Services, all from customers in the United States.

Market Cap: US$1.0 billion

HealthStream matters for this AI healthcare theme because its Competency Suite and related tools aim to turn clinician data into tailored training and staffing decisions across an entire workforce.

"Growing use of the hStream platform as an integrated system of record, with customers increasingly signing larger multi year bundles such as Competency Suite and targeted market bundles, can widen HealthStream’s revenue base and support steadier adjusted EBITDA margins as more applications connect through shared infrastructure."

What happens if one quiet shift in how hospitals value measurable workforce competency changes the balance between future pricing power and margin stability?

That shift in how hospitals price competency is exactly where the full narrative for HealthStream shows whether HealthStream’s AI could be quietly accelerating or masking future earnings power.

Seeking Fresh Alternatives Before Others?

Fresh ideas often move first, and the strongest themes can break out quietly while attention stays on yesterday’s winners. Review these under the radar lists before momentum becomes widely followed, and consider your options early.

• Identify early movers in smaller companies with real balance sheet strength by running the 20 high quality undiscovered gems before the crowd starts focusing on the same tickers.
• Explore durable income streams while yields remain appealing by scanning the 7 dividend fortresses, which focuses on reliable payouts and solid financial footing.
• Assess structural demand in critical metals by reviewing the curated 32 best rare earth metal stocks, which highlights producers connected to long term supply themes.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com